Semaglutide is a GLP-1 receptor agonist found in medicines including Wegovy and Ozempic, each with its own label and indications. The word semaglutide on another vial does not establish equivalent contents or evidence.
Substance names and product names differ
Wegovy and Ozempic are Novo Nordisk product names. Belzempic, SemaPure, Lunaris and BP entries are separate listings; compare substance, presentation and product documentation rather than similar names.
What STEP 1 can tell readers
STEP 1 studied adults with overweight or obesity under defined trial conditions. Its findings do not verify a BP vial or another brand, and a study average does not guarantee an individual outcome.
Precautions alongside medicine information
Labels describe nausea, vomiting or diarrhoea among adverse effects, alongside contraindications and other important risks. An indication does not make a medicine suitable for everyone; a clinician or pharmacist must consider health history and current medicines.
Frequently asked questions
Are Wegovy and Ozempic the same product name?
They are distinct product names associated with semaglutide. Check each presentation and label.
Does a Novo Nordisk label verify a BP vial?
No. Novo Nordisk labeling and studies do not verify another brand.
What does the combined Wegovy/Ozempic listing picture?
The reviewed primary image shows Wegovy. Identify the actual presentation before attaching Ozempic or other product information.
Read next
Semaglutide · What is tirzepatide? Medicine names, mechanism and listing differences · What is cagrilintide? Amylin analogue and CagriSema explained
Sources
- Novo Nordisk — Ozempic prescribing information
- Novo Nordisk — Wegovy prescribing information
- Wilding et al., 2021 — STEP 1
- FDA — Unapproved GLP-1 products
Information checked 10 September 2026. Research and medicine labels above are separate from evidence for this listing image.
For general name or label questions, contact LINE: @musclestationth